Pfizer’s BRAFTOVI® Combo Boosts Survival in Phase 3 BREAKWATER Trial Pfizer Inc. (NYSE: PFE) has announced promising results from the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with…
Henry Schein Announces Strategic Investment by KKR, Board Changes, and Provides Financial Results and 2025 Guidance Henry Schein, Inc. (Nasdaq: HSIC), the world’s leading provider of health care solutions for…
Cardinal Health Reports Q2 FY25 Results, Raises Outlook Cardinal Health Reports Strong Q2 FY25 Results and Strategic Growth Moves Revenue and Earnings Overview Cardinal Health (NYSE: CAH) has reported a…
Aetna Better Health of Illinois, a CVS Health company (NYSE: CVS), has introduced three new lifestyle benefits designed to support its Medicaid members enrolled through the HealthChoice Illinois program. These…
Tubulis Advances ADC TUB-030 into Clinical Trials for Advanced Solid Tumors Tubulis, a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced a significant milestone today with the dosing of the…
Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, has announced a significant milestone with the 510(k) clearance from the FDA and MDR certification in the European…
Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium Parabilis Medicines, formerly known as Fog Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing transformative…
Charles River Expands Apollo™ Ecosystem with Custom Client Experiences Charles River Laboratories International, Inc. (NYSE: CRL) today introduced Apollo™ for CRADL®, a secure cloud-based platform designed to enhance its vivarium…
Heart & Kidney Health Screening Available for Free in Seattle, Jan 22-24 Care Access, a health and research company, is offering its Heart & Kidney Health Screening initiative to residents…
Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type DATROWAY® (datopotamab deruxtecan-dlnk), an innovative TROP2-directed antibody-drug conjugate (ADC), has been approved by the U.S. Food and…
Announces TripleBlind Exchange: Selfii’s Secure HIPAA-Compliant Health Data Access Selfii, a leader in privacy-preserving health data solutions for individuals and healthcare organizations, announces the launch of its groundbreaking data marketplace,…
Agreement Between Neuraly and Enigma Biomedical USA on PET Imaging Biomarker PMI04 On January 16, 2025, Neuraly Inc., a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA,…